DEMANE MICHAEL F 4
4 · NEVRO CORP · Filed Apr 14, 2023
Insider Transaction Report
Form 4
NEVRO CORPNVRO
DEMANE MICHAEL F
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2023-04-12$18.00/sh+80,291$1,445,238→ 101,018 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-04-12−80,291→ 0 totalExercise: $18.00Exp: 2024-11-05→ Common Stock (80,291 underlying)
Holdings
- 164,344(indirect: See footnote)
Common Stock
- 91,225(indirect: See footnote)
Common Stock
- 82,541(indirect: See footnote)
Common Stock
- 18,266(indirect: See footnote)
Common Stock
Footnotes (6)
- [F1]Includes 4,155 restricted stock units.
- [F2]Shares held by Catherine Q. DeMane Trustee, Michael F. DeMane 2012 Irrevocable Trust U/A/D July 26, 2012.
- [F3]Shares held by Catherine Q. DeMane Trustee, Michael F. DeMane 2017 Family SLAT Trust U/A/D May 22, 2017.
- [F4]Shares held by Michael F. DeMane & Catherine Q. DeMane, Trustees, Michael F. DeMane Revocable Trust U/A 10/07/2011.
- [F5]Shares held by Michael F. DeMane, Trustee, Michael F. DeMane 2021 Retained Annuity Trust U/A 08/13/2021.
- [F6]The shares subject to the option are fully vested and exercisable.